Effects of bortezomib on the immune system: A focus on immune regulation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 10, 2013, Pages 1416-1420

  Mohty, Mohamad ^a,b,c   Brissot, Eolia ^c,d   Savani, Bipin N ^e   Gaugler, Beatrice ^f  

^a Unite de Therapie Cellulaire   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Team 12   (France)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f RIGHT Interactions Hôte Greffon Tumeur Ingénierie Cellulaire et Génique   (France)

Author keywords

Bortezomib; Graft versus host disease; Immune system; Proteaome inhibitor

Indexed keywords

ANTIRHEUMATIC AGENT; BORTEZOMIB; CORTICOSTEROID; GLUCOCORTICOID; IMMUNOGLOBULIN; METHOTREXATE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIANGIOGENIC ACTIVITY; ANTIBODY MEDIATED REJECTION; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CELL SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LUPUS VULGARIS; MULTIPLE SCLEROSIS; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; TRANSPLANTATION TOLERANCE;

BORTEZOMIB; GRAFT-VERSUS-HOST DISEASE; IMMUNE SYSTEM; PROTEAOME INHIBITOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; IMMUNE SYSTEM; MULTIPLE MYELOMA; PYRAZINES;

EID: 84884209657     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.05.011     Document Type: Review

References (64)

1. Adams J. Proteasome inhibition in cancer: Development of PS-341. Semin Oncol 2001, 28:613-619.
2. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
3. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002, 99:14374-14379.
4. Zwickl P., Voges D., Baumeister W. The proteasome: A macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 1999, 354:1501-1511.
5. Baldwin A.S. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 1996, 14:649-683.
6. Richardson P.G., Hideshima T., Anderson K.C. Bortezomib (PS-341): A novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003, 10:361-369.
7. Ondrey F.G., Dong G., Sunwoo J., et al. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol Carcinog 1999, 26:119-129.
8. Berenson J.R., Ma H.M., Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 2001, 28:626-633.
9. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. JBiol Chem 2002, 277:16639-16647.
10. Wang X., Luo H., Chen H., et al. Role of proteasomes in T cell activation and proliferation. JImmunol 1998, 160:788-801.
11. Wu J. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant 2002, 2:904-912.
12. Orlowski R.Z., Small G.W., Shi Y.Y. Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. JBiol Chem 2002, 277:27864-27871.
13. Hideshima T., Chauhan D., Schlossman R., et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene 2001, 20:4519-4527.
14. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7:1419-1428.
15. Pamer E., Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998, 16:323-358.
16. Rock K.L., Goldberg A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999, 17:739-779.
17. Mattingly L.H., Gault R.A., Murphy W.J. Use of systemic proteasome inhibition as an immune-modulating agent in disease. Endocr Metab Immune Disord Drug Targets 2007, 7:29-34.
18. Nencioni A., Grunebach F., Patrone F., et al. Proteasome inhibitors: Antitumor effects and beyond. Leukemia 2007, 21:30-36.
19. Finn P.W., Stone J.R., Boothby M.R., Perkins D.L. Inhibition of NF-kappaB-dependent T cell activation abrogates acute allograft rejection. JImmunol 2001, 167:5994-6001.
20. Berges C., Haberstock H., Fuchs D., et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 2008, 124:234-246.
21. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107:3575-3583.
22. Blanco B., Perez-Simon J.A., Sanchez-Abarca L.I., et al. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T cell population. Haematologica 2009, 94:975-983.
23. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004, 101:8120-8125.
24. Vodanovic-Jankovic S., Hari P., Jacobs P., et al. NF-kappaB as a target for the prevention of graft-versus-host disease: Comparative efficacy of bortezomib and PS-1145. Blood 2006, 107:827-834.
25. Sun K., Wilkins D.E., Anver M.R., et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005, 106:3293-3299.
26. Mateos-Mazon J., Perez-Simon J.A., Lopez O., et al. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica 2007, 92:1295-1296.
27. Wang X.C., Jobin C., Allen J.B., et al. Suppression of NF-kappaB-dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor. Invest Ophthalmol Vis Sci 1999, 40:477-486.
28. El-Cheikh J., Michallet M., Nagler A., et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008, 93:455-458.
29. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.
30. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. JClin Oncol 2012, 30:3202-3208.
31. Stegall M.D., Gloor J.M. Deciphering antibody-mediated rejection: New insights into mechanisms and treatment. Curr Opin Organ Transplant 2010, 15:8-10.
32. Nankivell B.J., Alexander S.I. Rejection of the kidney allograft. NEngl J Med 2010, 363:1451-1462.
33. Perry D.K., Burns J.M., Pollinger H.S., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.
34. Everly M.J., Everly J.J., Susskind B., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86:1754-1761.
35. Walsh R.C., Everly J.J., Brailey P., et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010, 89:277-284.
36. Flechner S.M., Fatica R., Askar M., et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010, 90:1486-1492.
37. Idica A., Kaneku H., Everly M.J., et al. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transplant 2008, 229-239.
38. Trivedi H.L., Terasaki P.I., Feroz A., et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009, 87:1555-1561.
39. Everly M.J., Everly J.J., Susskind B., et al. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 2009, 41:105-107.
40. Hardinger K.L., Alford K., Murillo D. Bortezomib for acute humoral rejection in two repeat transplant recipients. Clin Transplant 2009, 479-483.
41. Lachmann N., Schutz M., Budde K., et al. Antihumoral rejection therapy by proteasome inhibitor bortezomib: A case series. Clin Transplant 2009, 351-358.
42. Mai H.L., Cesbron A., Brouard S., et al. Bortezomib in the treatment of antibody-mediated rejection-a report of 3 cases. Clin Transplant 2009, 361-368.
43. Hamawi K., Heilman R.L., Mazur M.J., et al. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients-case report. Clin Transplant 2009, 407-414.
44. Sberro-Soussan R., Zuber J., Suberbielle-Boissel C., et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010, 10:681-686.
45. Wong W., Lee R.A., Saidman S.L., et al. Bortezomib in kidney transplant recipients with antibody mediated rejection: Three case reports. Clin Transplant 2009, 401-405.
46. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
47. Fries J.F. Current treatment paradigms in rheumatoid arthritis. Rheumatology (Oxford) 2000, 39(Suppl 1):30-35.
48. Finckh A., Choi H.K., Wolfe F. Progression of radiographic joint damage in different eras: Trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 2006, 65:1192-1197.
49. Vaz A., Lisse J., Rizzo W., Albani S. Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases. Expert Rev Clin Immunol 2009, 5:291-299.
50. Feely M.G., Erickson A., O'Dell J.R. Therapeutic options for rheumatoid arthritis. Expert Opin Pharmacother 2009, 10:2095-2106.
51. Buch M.H., Emery P. New therapies in the management of rheumatoid arthritis. Curr Opin Rheumatol 2011, 23:245-251.
52. Jue D.M., Jeon K.I., Jeong J.Y. Nuclear factor kappaB (NF-kappaB) pathway as a therapeutic target in rheumatoid arthritis. JKorean Med Sci 1999, 14:231-238.
53. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
54. Dayer J.M. Interleukin 1 or tumor necrosis factor-alpha: Which is the real target in rheumatoid arthritis?. JRheumatol Suppl 2002, 65:10-15.
55. Roman-Blas J.A., Jimenez S.A. Targeting NF-kappaB: A promising molecular therapy in inflammatory arthritis. Int Rev Immunol 2008, 27:351-374.
56. Yannaki E., Papadopoulou A., Athanasiou E., et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum 2010, 62:3277-3288.
57. Lee S.W., Kim J.H., Park Y.B., Lee S.K. Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 2009, 68:1761-1767.
58. van der Heijden J.W., Oerlemans R., Lems W.F., et al. The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 2009, 27:92-98.
59. Fissolo N., Kraus M., Reich M., et al. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 2008, 38:2401-2411.
60. Schmidt N., Gonzalez E., Visekruna A., et al. Targeting the proteasome: Partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 2010, 59:896-906.
61. Nencioni A., Schwarzenberg K., Brauer K.M., et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006, 108:551-558.
62. Hirai M., Kadowaki N., Kitawaki T., et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 2011, 117:500-509.
63. Roccaro A.M., Hideshima T., Raje N., et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006, 66:184-191.
64. Moschetta M., Di Pietro G., Ria R., et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010, 46:420-429.